CORE-ABR

Resistance gene

Class C beta-lactamase (AmpC)

Predicts: AmpC cephalosporinase production. Reported qualitatively as detected or not detected.

Qualitative PCR targetApplied per organism

Mechanism

A serine cephalosporinase that is not inhibited by clavulanate. Chromosomal in some species, plasmid-borne in others.

What it removes from the grid

Penicillins, amoxicillin-clavulanate, cephamycins and most cephalosporins.

What it spares

Cefepime and the carbapenems generally retain activity.

A multiplex panel can't say which organism in a mixed specimen carries a detected gene. CORE-ABR applies Class C beta-lactamase (AmpC) only to organisms known to carry it, and only to the agents its mechanism defeats — so a detected gene moves the right cells and spares the rest.

Organisms it is applied to

Coding

Z16.19 (resistance to other specified beta lactam antibiotics), as documentation supports. CORE-ABR adds resistance findings as supporting codes, not primary, and prints the rationale on the report.

Tagged

Decision support only. The treating clinician decides. Molecular genotype does not replace phenotypic susceptibility testing, culture, or public-health reporting. Absence of a detected resistance gene does not establish susceptibility. Organism targets vary by panel; CORE-ABR is configured to the assay each laboratory runs.